Yang et al. (2022) encapsulated raloxifene in human serum albumin (HSA)-based nanoparticles as an intravenous drug formulation, which significantly increased bioavailability and improved its half-life in plasma, and could be a potential nanomedicine for the treatment of postmenopausal osteoporosis. The gene discussed is ALB; the disease is postmenopausal osteoporosis.